Binder and Disintegrant Functions Are Not Mutually Exclusive in Companion Animal Tablet Lines

In high-speed rotary tablet compression of veterinary antiparasitic and nonsteroidal anti-inflammatory drug formulations, sodium carboxymethylcellulose with a degree of substitution between 0.65 and 0.90 and a viscosity of 200–800 mPa·s as a 1% solution is introduced intragranularly at 1.5–4.0% w/w dry-mix basis or as a 1–3% w/v aqueous granulating fluid. The polymer functions simultaneously as a wet-granulation binder and, after drying, as an intragranular disintegrant: during wet massing in a high-shear granulator with impeller tip speed 5–10 m/s and chopper speed 1000–3000 rpm, hydrated CMC forms liquid bridges; upon contact with gastrointestinal fluid, low-substituted regions swell and generate internal tablet stress. Compression on a rotary tablet press at 10–25 kN compression force produces tablets with hardness 50–120 N and friability below 1.0% when tested under Ph. Eur. 2.9.7. Compliance for this application rests on the current USP-NF monograph for carboxymethylcellulose sodium, Ph. Eur. monograph 0472, dissolution testing according to USP <711> or Ph. Eur. 2.9.3, uniformity of dosage units under Ph. Eur. 2.9.40 or USP <905>, and residual solvent class limits under VICH GL18(R2). Downstream process control includes dry blending in bin blenders for 10–15 min, wet massing to an end-point torque rise of 15–30% above dry baseline, wet screening through 0.8–2.0 mm sieves, fluid-bed drying at inlet air 55–70 °C until loss-on-drying 1.0–2.5%, and final blending with magnesium stearate prior to compression. Terminal finished product types include scored chewable antiparasitic tablets, film-coated NSAID tablets for dogs, and multi-strength compressed tablets packed in blister or high-density polyethylene containers.

Where aqueous suspensions of poorly soluble veterinary actives such as triclabendazole, fenbendazole, or potentiated sulfonamides are filled into multi-dose oral drench bottles, carboxymethylcellulose sodium is hydrated at 0.25–0.80% w/v to generate a pseudoplastic vehicle with viscosity 50–300 mPa·s at 20 °C and pH 6.0–8.0. The anionic polymer increases continuous-phase viscosity and contributes electrostatic repulsion at the suspended particle surface, reducing sedimentation velocity and caking at the container base. Production begins with cold-water dispersion under high-shear mixing at 1500–3000 rpm to avoid gel-blocking, followed by low-shear hydration under vacuum for 60–120 min, API addition through a colloid mill or high-shear disperser, deaeration at −0.06 to −0.09 MPa, and filling into amber polyethylene terephthalate or high-density polyethylene bottles with tamper-evident closures. Industry compliance standards for this oral liquid segment include Ph. Eur. 0472 for carmellose sodium, Ph. Eur. 2.2.10 for viscosity, Ph. Eur. 2.9.40 for uniformity of dosage units, Ph. Eur. 5.1.3 for efficacy of antimicrobial preservation in multi-dose aqueous systems, and VICH GL18(R2) for residual solvent class limits. Terminal finished product types include oral drench suspensions for sheep and cattle, multi-dose liquid dewormers for horses, and companion animal oral suspensions filled into calibrated syringe or bottle assemblies.

Why Does Terminal Autoclaving Shift the Viscosity Profile of CMC-Stabilized Injectable Suspensions?

During aseptic manufacture of long-acting parenteral suspensions for cattle, sheep, and pigs, sodium carboxymethylcellulose is used at 0.5–1.2% w/v in water for injection to retard settling of micronized active pharmaceutical ingredients such as oxytetracycline, amoxicillin trihydrate, or ivermectin. The polymer is depyrogenated and hydrated in a jacketed stainless-steel vessel with an impeller speed of 200–600 rpm; if the CMC phase is exposed to terminal moist-heat sterilization at 121 °C for 15 min, chain scission can reduce low-shear viscosity and widen particle-size distribution after cooling, so many manufacturing lines select aseptic hydration from gamma-irradiated or dry-heat depyrogenated powder and combine the sterile CMC solution with separately sterilized API through a low-shear aseptic mixing loop at ≤25 °C. Published data for this specific moisture-heat exposure curve are limited; terminal-sterilization cycles therefore require batch-specific viscosity re-qualification after autoclaving. The API is typically controlled before suspension by air-jet milling to D90 <15 µm, then dispersed with a high-pressure homogenizer at 400–800 bar first-stage pressure to break agglomerates and coat particles with the polymer. Compliance requirements for this parenteral route include Ph. Eur. monograph 0472 with additional bacterial endotoxin control below 0.5 EU/mg where used parenterally, Ph. Eur. 2.6.1 sterility, Ph. Eur. 2.6.14 bacterial endotoxin for the finished product, Ph. Eur. 2.9.19 particulate contamination for suspensions for injection, and current EU GMP Annex 1 for sterile veterinary medicinal products. Terminal finished product types include ready-to-use injectable suspensions in multidose polyethylene or glass vials, intramammary syringes for dry-cow therapy, and long-acting subcutaneous injection suspensions.

Premix plants operating ribbon blenders with spray-bar granulation often use carboxymethylcellulose sodium at 0.2–1.5% w/w in medicated premixes intended for oral administration through feed, where the polymer functions as a binder, anti-dusting agent, and stabilizer for moisture-sensitive actives such as coccidiostats, direct-fed microbials, and mineral boluses. The addition ratio is operated as a narrow band: below 0.2% w/w the dust suppression effect is marginal in high-speed transfer augers, while above 1.5% w/w the premix can segregate after silo storage due to changes in particle surface moisture. Process control includes dry blending in a ribbon blender at 20–40 rpm for 8–15 min, injecting a 1–2% w/v CMC solution through a spray bar at 1.0–2.5 bar atomizing air, granulation on a fluid bed with inlet air 55–75 °C to product moisture 3–6%, and final screening through 1.0–3.0 mm mesh. Industry compliance standards applicable to this feed-medicated premix segment are Regulation (EC) 1831/2003 for feed additives, the FAMI-QS Code of Practice for feed additive and premixture operators, and HACCP-based feed safety controls under current EU feed hygiene legislation. Terminal finished product types include granulated premix in 5–25 kg paper or polyethylene-lined bags, direct-fed microbial premixes, mineral boluses, and soluble powders for drinking water with high dispersibility.

Oral Paste Yield Stress and Syringeability in Equine Dewormer Formulations

Formulators adjusting oral paste yield stress in equine anthelmintic dosage syringes incorporate veterinary-grade CMC at 2.0–5.5% w/w combined with wetting agents and humectants to avoid syneresis during shelf storage. The polymer provides a yield stress of 50–250 Pa as measured by controlled-stress rotational rheometry at 20 °C, which prevents phase separation in the syringe before administration but permits extrusion through a 2–4 mm orifice at 10–40 N plunger force. The production process includes dry pre-blending of CMC with API in a planetary mixer at 20–60 rpm, addition of a glycerol/propylene glycol phase to wet the polymer, incorporation of an aqueous phase under vacuum of −0.08 MPa, and deaeration for 15–30 min until air content falls below 1.5% v/v. Filling is performed on volumetric syringe fillers with bottom-up nozzles to reduce air entrapment, followed by torque verification at 0.2–0.8 N·m on cap closures. CMC is incompatible with high concentrations of soluble aluminum or iron salts, which can reduce viscosity and cause syneresis; this boundary must be checked when trace mineral premixes are co-formulated. Compliance standards for this segment include Ph. Eur. monograph 0472, Ph. Eur. 2.2.10 for viscosity, Ph. Eur. 2.9.5 for uniformity of mass of single-dose preparations, and the current VICH stability guidance for veterinary medicinal products in relevant climatic zones. Terminal finished product types include multi-dose equine dewormer paste syringes calibrated by body weight, single-dose cattle oral paste syringes, and companion animal nutraceutical gels that require similar pseudoplastic flow but lower active loading.

Dissolved in drinking water lines, the dry blend of water-soluble antibiotics and electrolytes in sachets frequently fails wetting tests unless the formulation includes a small mass fraction of carboxymethylcellulose sodium at 0.5–2.0% w/w. The polymer acts as a dispersant during the first 30–60 s of reconstitution, reducing lump formation when the sachet contents are added to a stock tank under agitation at 200–500 rpm; it also reduces air entrainment at the liquid surface. For insoluble actives that will be administered as a suspension in drinking water, the CMC fraction is increased to 1.0–2.0% w/w and co-processed with silica or calcium carbonate to improve dry flow. Production begins with a double-cone blender or V-blender charged with active pharmaceutical ingredient, citric acid, sodium bicarbonate if effervescence is required, and CMC, mixed for 10–20 min; the blend is then filled into aluminum-lined sachets at 25–35 °C and 20–30% relative humidity to prevent moisture uptake. Compliance standards include Ph. Eur. monograph 0472 for the polymer, Ph. Eur. 2.9.40 for uniformity of dosage units of the filled sachet, Ph. Eur. 5.1.3 if the reconstituted solution is multi-dose and preserved, and the EU feed additive framework under Regulation (EC) 1831/2003 when the powder is delivered through medicated water. Terminal finished product types include water-dispersible granules for poultry and swine, soluble powders for oral solution in drinking water, and effervescent sachets or tablets intended for dissolution prior to herd administration.